Eli Lilly Reports post-marketing Data for Gantenerumab in Ovarian cancer

Eli Lilly today announced post-marketing results for gantenerumab in patients with ovarian cancer. The study demonstrated that gantenerumab achieves clinical remission compared to standard of care or placebo. These results provide important insights into the treatment of ovarian cancer and support the continued development of gantenerumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.